Leukemia/Lymphoma/Hematologic Malignancies
The CINJ Hematologic Malignancies Tumor Study Group is a university-wide multi-disciplinary group of disease-oriented physicians, scientists, nurses, social workers and other staff members dedicated to optimizing therapy for patients with acute and chronic leukemias, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, myelodysplasia, myeloproliferative diseases, and other hematologic malignancies. Novel CINJ laboratory studies and investigator-initiated clinical trials complement studies developed by national cooperative groups and pharmaceutical companies to assure a broad research agenda focused on learning more about the biology of these diseases and improving currently available therapies. Members of the Hematologic Malignancies Tumor Study Group include: (i) physicians with interest and expertise in the clinical management of leukemia, lymphoma and related diseases; (ii) basic scientists that perform laboratory studies relevant to the biology and treatment of these diseases; (iii) translational scientists that perform studies designed to convert laboratory findings into information of particular clinical relevance; (iv) clinical investigators who work closely with basic and translational scientists to develop trials that test new therapies for patients with leukemia, lymphoma or related diseases; (v) nurse practitioners who specialize in the care of patients with these diseases; (vi) transplant coordinators who care for patients in the process of evaluation for transplantation or novel cellular immune therapies; (vii) research nurses who help assure that our clinical trials meet the individualized needs of our patients; (viii) clinical research personnel who help develop and analyze clinical trials and data; (ix) treatment nurses who have expertise in the administration of various disease-specific therapies; (x) pharmacists who participate in the development and implementation of treatment plans; (xi) social workers who provide a wide spectrum of psychological, emotional and other support services for patients confronted with leukemia, lymphoma and related diseases; and (x) clinical support staff who facilitate patient visits to our office. The Hematologic Malignancies Tumor Study Group focuses on a broad spectrum of disease-related issues. Ongoing research efforts address multiple aspects of disease biology and patient management. The multidisciplinary group meets frequently and sponsors a variety of research, patient-oriented, and educational meetings. In particular, the group understands the patient and family stresses associated with the diagnosis and treatment of leukemia, lymphoma and related diseases, and makes every effort to assure prompt and collaborative patient evaluation. The Stem Cell Transplantation Program at CINJ is conducted in conjunction with the Robert Wood Johnson University Hospital for in-patient care. Physicians actively perform stem cell transplants on a variety of illnesses where this treatment is indicated. These include acute and chronic leukemias, myelodysplasia, lymphomas both low and high-grade, chronic lymphocytic leukemia, Hodgkin's disease and myeloma. Both autologous and allogeneic transplants are performed. Useful Links From The Resource and Learning Center: Hodgkin's Disease Staff of this Program: |
Pediatric Hematology/Oncology Program
Adult Oncology Program
Breast Oncology - The New Jersey Comprehensive Breast Care Center Gastrointestinal/Hepatobiliary Oncology Program Leukemia/Lymphoma/Hematologic Malignancies Liver Cancer and Bile Duct Cancer Care Program Melanoma and Soft Tissue Oncology Program Phase I/Developmental Therapeutics Prostate Cancer: Dean and Betty Gallo Prostate Cancer Center Stem Cell Transplantation Program
|
